Aura Biosciences (NASDAQ:AURA) Issues Earnings Results

Aura Biosciences (NASDAQ:AURA) released its quarterly earnings data on Tuesday. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02, Zacks reports.

Aura Biosciences Trading Down 3.5 %

NASDAQ:AURA opened at $9.97 on Friday. The company’s 50-day moving average is $9.75 and its two-hundred day moving average is $8.50. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38.

Analyst Ratings Changes

A number of research firms have recently commented on AURA. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Scotiabank upped their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research note on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $23.00.

Insider Buying and Selling at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.04, for a total value of $300,903.68. Following the transaction, the insider now directly owns 329,847 shares in the company, valued at approximately $3,971,357.88. This represents a 7.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Julie B. Feder sold 25,131 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.03, for a total transaction of $302,325.93. Following the sale, the chief financial officer now directly owns 134,276 shares in the company, valued at approximately $1,615,340.28. The trade was a 15.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,259 shares of company stock worth $780,699 in the last ninety days. 5.40% of the stock is owned by insiders.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.